Coronavirus Stock Market: New Opportunities Rise With the Vaccine

This article was written by Gabriel Plat, a Financial Analyst at I Know First.

Summary:

  • The vaccine is closer than we thought. Pfizer and BioNTech plan to distribute it by 2021;
  • AHT grew 228% in 3 days, indicating opportunities that might be available when the pandemic is over;
  • The entertainment and flight industries can be a huge opportunity to look at;
  • I Know First algorithm is the best way to maximize your profit amid these opportunities.

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

NVAX Stock Forecast: Global Rollout Of Covid-19 Vaccines & Buy Rating

Viktoria VoronchukThis NVAX stock prediction article was written by Viktoriya Voronchuk – Financial Analyst intern I Know First.

Summary:

  • Over the past month, the NVAX stock is up 69%: Investors believe Novavax is a major competitor for the vaccine from covid-19
  • Novavax spent 113,84 thousand $ on research and development: more than competitors in the biotech sector
  • The average growth rate for the last 8 years shows that NVAX 's stock target price should be around 145.15 $ for the next year

premiumRead The FullPremium Article

Subscribe to receive exclusive PREMIUM content here

Winning Stock Forecast: CCL, KSS, MT Bounced Hard in 3 Days

Kohl’s  partnership with Sephora shops – 27.02 % increase in 3 days

(Source: www.wpxi.com)

On December 4, I Know First issued a 3-days winning stock forecast for KSS with a strong bullish signal of 0.29 and the predictability of 0.22. 3 days later, KSS stock rose from $36.52 to $40.90. This 27.02% surge was in line with our forecast.

Kohl’s holds the No. 2 ranks among its peers in the Retail-Department Stores industry group in the United States. The main reason for the rise in Kohl’s stock is a long-term strategic partnership with Sephora shops. Sephora is a popular prestige brand and a proven traffic driver. The companies said that the new partnership, “Sephora at

Read More

DVAX Stock Forecast: High-risk Player Amidst Potential COVID Vaccine

The Tesla stock forecast was written by Hugh Camiener, Analyst at I Know First. Bachelor of Arts candidate at Columbia University.

Summary

  • Dynavax is a commercial state biopharmaceutical company which develops and commercializes vaccines..
  • Dynavax has an FDA approval on their Hepatitis B vaccine, and they have partnered with Sinovac in developing a vaccine for COVID. 
  • The pandemic has caused a significant decline in Dynavax’s revenue, with their net product revenue falling 71% in comparison to Q2 last year.
  • Dynavax’s vaccine partnership with Sinovac has shown positive signs in phase 1 and phase 2 of testing, and their vaccine will be entering phase 3 in Brazil.
  • There is a large amount of volatility in the biopharmaceutical industry; amidst Russia’s self-proclaimed vaccine, Dynavax’s stock fell 9.7%.
  • Dynavax stock forecast remains a high-risk, high reward option..

Read The Full Premium Article

Subscribe to receive exclusive PREMIUM content Here

DVAX Stock Forecast: Table Is Being Set – Revenue Growth Is On The Way

 

The article was written by Amber Zhou, a Financial Analyst at I Know First.

DVAX Stock Forecast

“We believe there’s a great opportunity for Dynavax to contribute to the overall health of the adult population with diabetes”—said Dr. Rob Janssen, chief medical officer of Dynavax.

(Source: mmm-online.com)

 

Highlights:

  • Competitive Edge and Huge Market Potential from Heplisav-B®
  • Market Doubts about Trial Data of Immuno-Oncology Platform
  • Strong Cash Position from Debt Financing
  • Current I Know First Bullish Forecast For DVAX

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

Quick Win By The Algorithm: DVAX shows strong return and bright future